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ABSTRACT
Objectives To propose an improvement on the current
classification of renal dysfunction in cirrhosis. Clinicians
caring for patients with cirrhosis recognize that the
development of renal dysfunction is associated with
significant morbidity and mortality. While most cases of
renal dysfunction in cirrhosis are functional in nature,
developed as a result of changes in haemodynamics,
cardiac function, and renal auto-regulation, there is an
increasing number of patients with cirrhosis and structural
changes in their kidney as a cause of renal dysfunction.
Therefore, there is a need for a newer classification to
include both functional and structural renal diseases.
Design A working party consisting of specialists from
multiple disciplines conducted literature search and
developed summary statements, incorporating the renal
dysfunction classification used in nephrology. These
were discussed and revised to produce this proposal.
Setting Multi-disciplinary international meeting.
Patients None.
Interventions Literature search using keywords of
cirrhosis, renal dysfunction, acute kidney injury (AKI),
chronic kidney injury (CKD), and hepatorenal syndrome.
Results Acute kidney injury will include all causes of
acute deterioration of renal function as indicated by an
increase in serum creatinine of >50% from baseline, or
a rise in serum creatinine of$26.4mol/L ($0.3mg/dL) in
<48hours. Chronic renal disease will be defined as an
estimated glomerular filtration rate (GFR) of <60ml/min
calculated using the Modification of Diet in Renal Disease
6 (MDRD6) formula, recognising that the MDRD6 formula
is not perfect for the cirrhotic patients and this may
change as improved means of estimating GFR becomes
available. Acute on chronic kidney disease will be defined
as AKI superimposed on existing chronic renal disease
using the above definitions for AKI and CKD.
Conclusions Accepting this new classification will allow
studies into the epidemiology, incidence, prevalence,
natural history and the development of new treatments
for these subtypes of renal dysfunction in cirrhosis.
Acute kidney injury (AKI) is common in patients
with cirrhosis and ascites, occurring in up to 19% of
cirrhotic patients admitted to hospital. In addition,
chronic kidney disease (CKD) occurs in approxi-
mately 1% of all patients with cirrhosis.1
The combination of liver disease and renal
dysfunction can occur as a result of systemic
conditions that affect both the liver and the kidney
simultaneously. However, renal dysfunction
complicating primary disorders of the liver are
much more common. These may include structural
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Significance of this study
What is already known about this subject?
< Hepatorenal syndrome is a severe complication
of advanced cirrhosis with a poor prognosis if
left untreated.
< The diagnosis of hepatorenal syndrome requires
the patient fulfilling a set of diagnostic criteria.
< Once a diagnosis of hepatorenal syndrome is
made, treatments are available and these are
effective in up to 40% of patients.
What are the new findings?
< A proposal to broaden the diagnosis of renal
dysfunction in cirrhosis to include cases of
acute and chronic renal failure not meeting the
diagnostic criteria of hepatorenal syndrome
types 1 and 2, respectively.
< Acute kidney injury will include all causes of
acute deterioration of renal function as indicated
by an increase in serum creatinine of >50%
from baseline or a rise in serum creatinine of
$26.4 mmol/l ($0.3 mg/dl) in <48 h.
< Chronic renal disease will be defined as an
estimated glomerular filtration rate of <60 ml/
min for more than 3 months calculated using the
Modification of Diet in Renal Disease 6 formula.
< Acute on chronic kidney disease will be defined
as an acute kidney injury superimposed on
existing chronic renal disease using the above
definitions for acute kidney injury and chronic
kidney disease.
How might it impact on clinical practice in the
foreseeable future?
< The recognition of cases of renal dysfunction
outside the traditional definition of hepatorenal
syndrome will allow patients with lesser
degrees of renal dysfunction to receive treat-
ment.
< The acceptance of these broadened definitions
of renal dysfunction in cirrhosis will help to
design studies to assess the pathophysiology,
and thence to devise treatment strategies for
these patients.
< A better classification system may also secure
more correct diagnoses leading to earlier and
better treatment.
< This potentially could have a positive impact on
patient outcome, as patients will be treated
earlier in the natural history of renal dysfunction.
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renal diseases such as IgA nephropathy, membranous nephrop-
athy and cryoglobulinaemia, or renal dysfunction without
significant histopathological changes such as hepatorenal
syndrome (HRS). These episodes of renal dysfunction may occur
acutely and are associated with significant morbidity and
mortality. With improved understanding of renal complications in
cirrhosis and the advent of treatment options, there is now
a greater need to diagnose renal dysfunction in cirrhosis accurately.
The Acute Dialysis Quality Initiative (ADQI) is an ongoing
process that seeks to produce evidence-based recommendations
for the prevention and management of AKI.2 As AKI has not
been formally defined in patients with cirrhosis, members of the
ADQI and the International Ascites Club (IAC) formed
a Working Group in March 2010 to discuss the definition of renal
dysfunction (both acute and chronic) in patients with cirrhosis.
Members of the Working Group included specialists who are
experts in the pathophysiology and management of renal
dysfunction in cirrhosis and were selected from the membership
of the ADQI and IAC. They conducted a literature search and
developed summary statements which were discussed and
revised at the meeting. The participants of the joint ADQIeIAC
meeting are shown in appendix 1. The final summary statements
and directions for future research are the basis for this paper.
HISTORICAL PERSPECTIVE
The clinical entity we now know as HRS was originally
described by Flint in 1963.3 In 1959, Papper et al reported intense
renal vasoconstriction in an otherwise normal kidney in such
patients, paving the way for the understanding of the patho-
genesis of HRS.4 Epstein et al later confirmed renal vasocon-
striction using renal angiography in a patient with cirrhosis
dying from renal failure and demonstrated post-mortem filling
of all renal vessels to the periphery of the cortex, thus estab-
lishing the ‘functional nature’ of HRS.5
Rodes et al next identified three different outcome patterns in
cirrhotic patients with renal dysfunction6: (1) a rapidly
progressive course with a history of a complication closely
related to the onset of renal failure (this group was later classi-
fied as type 1 HRS); (2) patients with stable renal dysfunction
during hospitalisation but no obvious cause for renal failure
(type 2 HRS); and (3) patients with an initial similar course as
those in group 2 until some complication occurred that hastened
the course of renal failure. The outcome was worst for patients
in the first group and best for patients in the second group.
DEFINITION OF HEPATORENAL SYNDROME
In 1979, a group of international investigators defined HRS as
a progressive form of renal dysfunction that occurred in cirrhosis
and other severe parenchymal liver diseases,7 with features of
prerenal renal failure (low urine sodium concentration and
hyperosmolar urine) but without any improvement following
volume expansion. However, they recognised that some cases do
progress to acute tubular necrosis. Despite setting guidelines,
there continued to be confusion over what truly constituted
HRS. This led to an editorial in the Lancet8 suggesting the term
‘hepatic nephropathy ’ to distinguish functional renal failure
from any combination of renal failure occurring with liver
failure, such as paracetamol overdose causing combined liver and
renal failure.
In 1996, the IAC defined HRS as a syndrome that occurs in
patients with cirrhosis, portal hypertension and advanced liver
failure, characterised by impaired renal function with marked
abnormalities in the arterial circulation and activity of endoge-
nous vasoactive systems.9 Clinically, HRS was divided into two
types: type 1 or acute HRS was characterised by a rapidly
progressive reduction of renal function as defined by a doubling
of the initial serum creatinine to >220 mmol/l (2.5 mg/dl) or
a 50% reduction in the initial 24 h creatinine clearance to
<20 ml/min in <2 weeks; type 2 or chronic HRS was defined as
moderate renal failure that progressed gradually over weeks to
months with a serum creatinine of 133e220 mmol/l
(1.5e2.5 mg/dl).
The IAC updated the definition and diagnostic criteria for
HRS in 2005 (box 1).10 This came about because of an improved
understanding of the pathophysiology of HRS, the recognition
that it frequently follows bacterial infections (especially spon-
taneous bacterial peritonitis), the development of effective
treatments and improved survival for patients with HRS, espe-
cially type 1. HRS is therefore no longer necessarily a fatal
condition without liver transplantation.
PATHOPHYSIOLOGY OF HEPATORENAL SYNDROME
The following is a summary of the current understanding of the
pathophysiology of HRS (figure 1).
Portal hypertension as the initiator of haemodynamic changes
The development of cirrhosis is associated with distortion,
compression and even obliteration of the liver vasculature. In
addition, there is decreased intrahepatic production of vasodi-
lators and activated hypercontractile stellate cells.11 This overall
increased resistance to portal inflowdor portal hyper-
tension12dwill increase the shear stress on the splanchnic vessel
walls leading to increased production of various vasodilators
such as nitric oxide, causing splanchnic vasodilation.13 Several
other factors including increased bacterial translocation,
increased mesenteric angiogenesis and hyporesponsiveness of the
splanchnic vessels to vasoconstrictors also contribute to the
splanchnic vasodilation.14 The end result is a pooling of blood in
the splanchnic vascular bed, akin to a splanchnic steal
syndrome.15 The shunting of blood and excess vasodilators from
the splanchnic to the systemic circulation following the opening
of portal-systemic shunts related to increased portal pressure
also leads to systemic arterial vasodilation.16 The combined effect
causes a relative inadequacy of the systemic circulation, the
so-called ‘reduction in the effective arterial blood volume’,
thereby triggering a hyperdynamic circulation in these patients.17 18
Independent of these haemodynamic changes, portal hyper-
tension per se can lead to renal vasoconstriction via increased
Box 1 International Ascites Club (IAC) proposed
diagnostic criteria for hepatorenal syndrome10
< Cirrhosis with ascites
< Serum creatinine >133 mmol/l (1.5 mg/dl)
< No improvement in serum creatinine (decrease to a level of
#133 mmol/l or 1.5 mg/dl) after at least 2 days of diuretic
withdrawal and volume expansion with albumin. The
recommended dose of albumin is 1 g/kg body weight/day
up to a maximum of 100 g/day
< Absence of shock
< No current or recent treatment with nephrotoxic drugs
< Absence of parenchymal kidney disease as indicated by
proteinuria >500 mg/day, microhaematuria (>50 red blood
cells/high power field) and/or abnormal renal ultrasonography
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sympathetic nervous activity. For example, the elimination of
portal hypertension with the insertion of a transjugular intra-
hepatic portosystemic shunt (TIPS) is able to improve renal
blood flow19 associated with a reduction in sympathetic nervous
activity.20 The infusion of glutamine which increases hepatic
sinusoidal pressure, mimicking portal hypertension, reduces the
glomerular filtration rate (GFR).21 Finally, lumbar sympathetic
blockade in patients with HRS increases renal blood flow,
suggesting that the renal sympathetic activity is implicated in
the efferent arm of this hepatorenal reflex.22
Excess renal vasoconstriction
A reduced effective arterial blood volume results in the
compensatory activation of various vasoconstrictor systems. In
response, renal blood flow decreases with consequent reduction
in GFR. Normally, the kidneys maintain blood flow by
increasing production of renal vasodilators such as prostaglan-
dins and kallikrein. However, in patients with cirrhosis there is
an overall reduction in renal vasodilator production,15 23 thereby
favouring renal vasoconstriction.24 This renal hypoperfusion
further increases the production of various intrarenal vasocon-
strictors including angiotensin II and endothelin, causing further
deterioration of renal haemodynamics and renal function, occa-
sionally with glomerular ischaemia and mesangial constriction.25
Abnormal renal autoregulation
Renal autoregulation is the process whereby regulatory mecha-
nisms ensure that the kidneys receive a relatively constant blood
supply regardless of fluctuations in blood pressure. Below a crit-
ical threshold of 65 mm Hg, renal blood flow decreases in
proportion to renal perfusion pressure which, in turn, is
dependent on mean arterial pressure. In cirrhosis, there is
a progressive rightward shift of the renal autoregulation curve as
liver disease progressesdthat is, for every given renal perfusion
Figure 1 Pathophysiology of
hepatorenal syndrome: acute
precipitating event. HRS, hepatorenal
syndrome.
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pressure, there is a gradual reduction of renal blood flow as liver
disease advances.26 The patient with cirrhosis is therefore poised
to develop renal failure simply because of the presence of
advanced cirrhosis.
Abnormal cardiocirculatory function
The high cardiac output state of the hyperdynamic circulation
in decompensated cirrhosis means that there is limited cardiac
reserve in these patients, and further reductions in systemic
vascular resistance cannot be met with further increases in
cardiac output. Failure to maintain blood pressure further
compromises renal perfusion. In cirrhotic patients with ascites
and spontaneous bacterial peritonitis, and therefore further
arterial vasodilation as a result of the infection, those who went
on to develop HRS at infection resolution had significantly
lower cardiac output compared with baseline and also compared
with those who did not develop HRS. A relative inability to
increase cardiac output during stress, a condition known as
cirrhotic cardiomyopathy,27 28 may therefore be a risk factor for
the development of HRS.29 Indeed, a relative low cardiac output
and high plasma renin activity were significant predictors for the
development of HRS in cirrhosis with ascites.30 The fact that
blockage of a TIPS shunt with an angioplasty balloon instantly
reduces renal blood flow, which reverses upon deflation of the
balloon, confirms that a reduction or increase in venous return
and hence cardiac output has a direct bearing on renal haemo-
dynamics.31 Recently, the relationship between cardiac systolic
dysfunction and the risk of developing renal dysfunction in
cirrhosis was also confirmed, as well as the negative impact of
cardiac dysfunction on patient survival.32
All the above factors contribute to the gradual deterioration in
renal function as cirrhosis advances. Any event that causes an
abrupt deterioration in haemodynamics can lead to a rapid
decline in renal function, precipitating type 1 HRS (figure 1).
CURRENT DIAGNOSTIC CRITERIA FOR HEPATORENAL
SYNDROME: ADVANTAGES AND DISADVANTAGES
The most recent diagnostic criteria for HRS clearly delineated
which patients should be regarded as having HRS and therefore
receive specific treatment. However, the rigid cut-off value of
a serum creatinine level of 133 mmol/l (1.5 mg/dl) may limit
treatment to patients with the most severe degree of renal
dysfunction. The changes that predispose to the development of
HRS are not an ‘all-or-none’ phenomenon, but rather evolve
progressively with the natural history of cirrhosis (figure 2). It is
unclear whether patients who have milder degrees of renal
dysfunction will also experience adverse outcomes. If so, they
should also be offered treatment early rather than waiting until
the diagnostic criteria of HRS are reached. Additionally, serum
creatinine is notoriously inaccurate in the diagnosis of renal
dysfunction in cirrhosis.33 Although serum creatinine reflects
renal function in patients with compensated cirrhosis fairly
accurately, patients with decompensated cirrhosis often have
low serum creatinine levels relative to their GFR owing to
reduced production of creatinine from creatine in the liver and
significant muscle wasting.34 Thus, serum creatinine in patients
with decompensated cirrhosis can still be within the normal
range despite significant renal dysfunction.35
The use of creatinine clearance in cirrhosis to assess renal
function is also unreliable because of the falsely low serum
creatinine in these patients coupled with a relatively increased
renal tubular creatinine secretion compared with filtered creati-
nine. Furthermore, it requires a 24-h urine collection which is
often incomplete. Formulae such as the CockcrofteGault and
Modification of Diet in Renal Disease (MDRD)dwhich are
based on serum creatinine concentrationsdwill also over-
estimate the GFR in cirrhosis.36 37 Clearance techniques using
exogenous markers such as inulin or iothalamate provide a more
accurate measurement of GFR but are labour-intensive and
expensive.38 The use of a one-sample 51Cr-EDTA clearance
technique is much simpler. However, this method tends to
overestimate true renal function in patients with both volume
overload and ascites due to redistribution of tracer into the
ascitic and interstitial fluid. These problems in the estimation of
GFR are compounded by correcting for body surface area.39
Other biological markers such as cystatin C40 and neutrophil
gelatinase associated lipocalin (NGAL),41 although promising,
have not been validated in patients with advanced liver disease.
Therefore, until better measurements of GFR can be found and
validated, serum creatinine measurement remains the most
widely used method for estimating renal function in clinical
practice in patients with cirrhosis.42
Recognising the inadequacy of serum creatinine as an index of
renal function in cirrhosis, patients with milder degrees of renal
dysfunction may not be diagnosed until advanced renal failure
sets in. The ADQIeIAC Working Group therefore proposes the
following definitions for the diagnosis of renal dysfunction in
cirrhosis in order to help identify patients with milder renal
dysfunction for possible treatment. Since no studies have
been performed in cirrhosis using these proposed definitions,
they can best be regarded as expert opinions or level D evidence,
but they represent an important first step in the process of
standardising nomenclature and definitions in patients with
cirrhosis and renal dysfunction. It is planned that this empirical
proposed classification will be validated in prospective trials.
DEFINITION OF ACUTE KIDNEY INJURY IN CIRRHOSIS
In 2004 the ADQI Working Group developed a consensus defi-
nition and classification for AKI known as the RIFLE criteria
(R: renal risk, I: injury, F: failure, L: loss of kidney function, E: end-
stage renal disease) which stratified acute renal dysfunction into
grades of increasing severity based on changes in serum creatinine
and/or urine output (figure 3).43 To date, the RIFLE criteria have
been validated in over 500 000 patients with AKI44 45 and have
been shown to predict clinical outcomes with a progressive
increase in mortality with worsening RIFLE class.46 The Acute
Kidney Injury Network (AKIN), an independent collaborative
network consisting of experts from ADQI and several
nephrology and intensive care medicine societies, broadened the
definition of AKI to include an absolute increase in serum
creatinine of $26 mmol/l ($0.3 mg/dl) when documented to
occur within 48 h,47 since smaller increases in serum creatinine
than those considered in the RIFLE classification have been
Figure 2 Natural history of cirrhosis: acute precipitating event. AKI,
acute kidney injury; GFR, glomerular filtration rate.
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shown to be associated with an adverse outcome.48 Once
established, a staging system then defines the severity of the AKI
(table 1).
The spectrum of kidney disease in cirrhosis includes acute and
chronic conditions. Nephrologists distinguish acute and chronic
renal disease by an artificial timeline of 3 months. Using the
RIFLE/AKIN criteria for AKI, only a few patients with cirrhosis
and acute kidney dysfunction will meet the criteria for type 1
HRS and therefore the remainder will have to be regarded as
having AKI, be it structural or functional. Similarly, some
patients with cirrhosis will have CKD such as diabetic
nephropathy or mild renal dysfunction not reaching a serum
creatinine of 133 mmol/l (1.5 mg/dl), and therefore not meeting
the criteria for a diagnosis of type 2 HRS. HRS therefore only
describes a portion of cirrhotic patients with renal dysfunction.
The ADQIeIAC proposed that the term ‘hepatorenal disorders’
(HRD) be used to describe all concurrent kidney dysfunction in
patients with advanced liver diseasedwhether functional or
structural in naturedwhich fulfils the diagnostic criteria of AKI
or CKD or HRS (figure 4). Such a definition is not meant to
replace the current definition of HRS, but rather to be inclusive
of all patients with renal dysfunction so that a proper classifi-
cation of renal dysfunction and appropriate studies can be
conducted to define their prognosis and to devise treatment
options.
Using the creatinine criteria for AKI in patients with cirrhosis
will certainly identify many patients with acute renal dysfunc-
tion and normal serum creatinine but low GFR. The urine
output criteria for AKI may not be applicable in cirrhosis since
patients with refractory ascites may maintain a urine output of
<0.5 ml/kg/h even in the absence of AKI. The final consensus
proposal of the Working Party was to accept the definition of
AKI in cirrhosis as an increase in serum creatinine of >50%
from baseline or a rise in serum creatinine of $26.4 mmol/l
($0.3 mg/dl) in <48 h, irrespective of whether the cause of the
acute deterioration in renal function is related to a functional or
structural disorder (table 2). Type 1 HRS can be regarded as
a specific form of AKI. It was further agreed that these empirical
new diagnostic criteria of AKI for cirrhosis will be validated to
determine whether these smaller increases in serum creatinine
are associated with poor outcomes. Two studies involving crit-
ically ill patients with cirrhosis admitted into an intensive care
unit already showed that the RIFLE criteria for AKI was a good
predictor of hospital survival.49 50
Once confirmed, the serum creatinine threshold for the diag-
nosis of type 1 HRS may need to be revised to a lower target
value. This has the potential to allow patients with a smaller rise
in creatinine to benefit from treatments currently reserved for
patients with classical HRS. This new classification will also
allow studies of the epidemiology, incidence, prevalence and
natural history of various subtypes of AKI in cirrhosis, thereby
allowing the development of potential preventive and treatment
strategies.
DEFINITION OF CHRONIC KIDNEY DISEASE IN CIRRHOSIS
Patients with chronic renal impairment related to cirrhosis may
not fit the definition and staging of CKD (table 3) as set out by
the practice guidelines from the Kidney Disease Outcomes
Quality Initiatives (K/DOQI) Workgroup,51 since it requires
a GFR of <60 ml/min/1.73 m2 for >3 months, irrespective of
the presence or absence of structural kidney damage. As
mentioned above, estimation of GFR in cirrhosis using various
formulae is problematic and actual measurement of GFR using
iothalamate or inulin clearance techniques are cumbersome and
essentially only performed for research purposes. Therefore, the
application of the definition of CKD in cirrhosis is challenging.
When the serum creatinine reaches the threshold of 133 mmol/l
(1.5 mg/dl), the patient is said to have type 2 HRS.
The prognosis of patients with cirrhosis and CKDdwhether
type 2 HRS or structural renal diseasedis worse than the
corresponding stage of CKD in non-cirrhotic patients because of
coexisting liver disease. Therefore, unlike non-cirrhotic patients,
these patients usually do not survive long enough for the CKD
to slowly deteriorate, nor will their CKD typically decline to the
point of requiring dialysis unless AKI supervenes. Nevertheless,
to be useful, a HRD classification system must include all
potential scenarios where CKD and advanced liver disease
coexist, either as independent entities or as the result of complex
organ interactions. For example, a patient with cirrhosis due to
non-alcoholic steatohepatitis may also have CKD on the basis of
diabetes. Similarly, a patient with cirrhosis and ascites and mild
renal dysfunction below the level defined by type 2 HRS may
develop other forms of CKD such as IgA nephropathy related to
his alcoholic liver disease. Finally, patients in both of these
examples are likely to be at increased risk for AKI with various
precipitants such as radiocontrast dye or sepsis.
Further research is required to understand the clinical signifi-
cance of reaching K/DOQI criteria for CKD in a patient with
cirrhosis. Nevertheless, the Working Group proposed the defi-
nition of CKD as an estimated GFR of <60 ml/min calculated
Figure 3 The RIFLE (R: renal risk, I: injury, F: failure, L: loss of kidney
function, E: end-stage renal disease) diagnostic criteria.43 ARF, acute
renal failure; GFR, glomerular filtration rate; UO, urine output.
Table 1 The Acute Kidney Injury Network (AKIN) criteria for the definition and classification of AKI
(modified RIFLE criteria)43 47
AKI stage Serum creatinine criteria Urine output criteria
1 (Risk) Increase in serum creatinine of $26.4 mmol/l ($0.3 mg/dl) within
48 h or an increase of $150e200% (1.5e2-fold) from baseline
<0.5 ml/kg/h for >6 h
2 (Injury) Increase in serum creatinine to 200e299% (>2e3-fold) from baseline <0.5 ml/kg/h for >12 h
3 (Failure) Increase in serum creatinine to $300% (>3-fold) from baseline or serum
creatinine of $354 mmol/l ($4.0 mg/dl) with an acute increase of
$44 mmol/l ($0.5 mg/dl) or initiation of renal replacement therapy
<0.3 ml/kg/h for 24 h or
anuria for 12 h
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using the MDRD6 formula52 for >3 months for patients with
cirrhosis (table 2) rather than a serum creatinine-based defini-
tion, to be in line with the definition of CKD in other subspe-
cialties. The group also recognises that the MDRD6 formula
tends to overestimate the GFR, but this is the formula that
approximates most closely to GFR measurement using
125I iothalamate clearance, especially in patients with low GFR
of <40 ml/min.36 Future studies are therefore needed to
formulate a specific equation for the calculation of GFR with an
acceptable accuracy for patients with advanced cirrhosis and to
determine what threshold represents an increased risk in this
population. The use of imaging criteria or histology to diagnose
CKD was not considered by the group, as chronic renal damage
may well precede the appearance of small sized kidneys on
imaging and renal biopsy in patients with cirrhosis and coagu-
loapthy is associated with an increased risk of bleeding.
Furthermore, large volume ascites may preclude this tech-
nique.42
DEFINITION OF ACUTE-ON-CHRONIC KIDNEY DISEASE IN
CIRRHOSIS
Finally, it is important to recognise that AKI may also occur in
patients with cirrhosis and pre-existing renal dysfunction. The
clinician should not have any problem identifying the precipi-
tation of type 1 HRS with spontaneous bacterial peritonitis in
a patient with type 2 HRS as the definitions of types 1 and 2
HRS are well established. However, type 1 HRS may also
superimpose on CKD that does not fulfil type 2 HRS criteria,
either because the renal dysfunction is not severe enough or
because it is due to other forms of kidney disease (eg, diabetic
nephropathy). Under the current diagnostic criteria for HRS, this
scenario poses a diagnostic dilemma as the classical definition of
HRS does not permit the presence of any evidence of structural
renal damage. This may have potential clinical implications as
therapeutic interventions, such as a TIPS shunt, may not be
inserted into patients with mixed HRD when such interventions
are actually beneficial.53 54 We recognise that acute-on-chronic
renal failure does occur in cirrhosis, although much work is
needed to understand this entity better, particularly when forms
of HRD are mixed (eg, AKI superimposed on CKD in a patient
with advanced liver disease). The Working Group agreed that, at
present, an empirical definition of acute-on-chronic kidney
disease as an increase in serum creatinine of >50% from baseline
or a rise in serum creatinine of $26.4 mmol/l ($0.3 mg/dl) in
<48 h in a patient with cirrhosis whose baseline GFR is <60 ml/
min calculated with the MDRD6 formula for >3 months will be
adopted. Once again, both the acute deterioration in renal
function and the background chronic renal dysfunction can be
functional or structural in nature (table 2).
SUMMARY
Renal complications are common in cirrhosis, especially in
patients with refractory ascites, and they can negatively impact
survival. The IAC has set out clear diagnostic criteria for both
acute and chronic forms of HRS, but has not delineated guidelines
for the diagnosis of other forms of renal impairment in cirrhosis,
Figure 4 Classification of hepatorenal disorder (HRD). (A) Patients with
acute liver failure without pre-existing liver disease who present with
rapid worsening of renal function. (B) Spectrum of hepatorenal disorders
in patients with advanced cirrhosis. AKI, acute kidney injury; CKD,
chronic kidney disease; KD, kidney disease; HRS, hepatorenal syndrome.
Table 2 Proposed diagnostic criteria of kidney dysfunction in cirrhosis
Diagnosis Definition
Acute kidney injury Rise in serum creatinine of $50% from
baseline or a rise of serum creatinine by
$26.4 mmol/l ($0.3 mg/dl) in <48 h
HRS type 1 is a specific form of acute
kidney injury
Chronic kidney disease Glomerular filtration rate of <60 ml/min
for >3 months calculated using MDRD6
formula
HRS type 2 is a specific form of chronic
kidney disease
Acute-on-chronic kidney disease Rise in serum creatinine of $50% from
baseline or a rise of serum creatinine by
$26.4 mmol/l ($0.3 mg/dl) in <48 h in
a patient with cirrhosis whose glomerular
filtration rate is <60 ml/min for
>3 months calculated using MDRD6
formula
Both the acute deterioration in renal function and the background chronic renal dysfunction
can be functional or structural in nature.
HRS, hepatorenal syndrome; MDRD6, Modification of Diet in Renal Disease formula
calculated using six variables of serum creatinine, age, gender, albumin, blood urea nitrogen
and whether or not the patient is African-American.
Table 3 Definition and stages of chronic kidney disease based on
kidney disease outcomes quality initiatives (K/DOQI) guidelines51
Stage Description GFR (ml/min/1.73 m2)
I Kidney damage with normal or
increased GFR
$90
II Kidney damage with mildly
decreased GFR
60e89
III Moderately decreased GFR 30e59
IV Severely decreased GFR 15e29
V Kidney failure <15 (or dialysis)
Chronic kidney disease is defined as either kidney damage or glomerular filtration rate (GFR)
<60 ml/min/1.73 m2 for >3 months. Kidney damage is defined as pathological
abnormalities or markers of damage including abnormalities in blood or urine tests or
imaging studies.
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whether acute or chronic. Well-accepted definitions and staging
systems for CKD and AKI exist but have not been consistently
applied to patients with advanced liver disease. Working together,
the ADQI and IAC have proposed uniform standards for the
diagnosis of AKI and CKD in cirrhosis adapted from these
established definitions. These new diagnostic criteria are not
meant to replace the well-established diagnostic criteria of HRS,
but rather to broaden the scope to include other forms of renal
disease in cirrhosis. The Working Group recognises that these
diagnostic criteria will need to be validated in large cohorts of
patients and may need to be modified depending on the outcome
of these studies. Once confirmed, these diagnostic criteria will be
applied to the development of clinical trials to evaluate potential
treatment options for patients with HRD.
RECOMMENDATIONS FOR FUTURE RESEARCH
Future research will have to concentrate on improving our
understanding of renal dysfunction in cirrhosis. To achieve this,
the Working Group has suggested the following broad research
areas.
1. To collect data on the epidemiology in terms of incidence,
prevalence and basic demographics of patients with HRD
including AKI, CKD and acute-on-chronic HRD.
2. To study the natural history of HRD, especially to search for
precipitating factors for AKI, and to describe the rate of
decline of renal function in patients with CKD.
3. To find better markers for renal dysfunction in cirrhosis such
as cystatin C or NGAL. Alternatively, to determine the test
characteristics including cut-off values for serum creatinine
that define an increased risk for patients with HRD.
4. To determine whether the pathophysiology of type 2 HRS is
different or the same as that of type 1 HRS, but only a matter
of extent.
5. To investigate whether patients with various forms of CKD
are at risk of developing type 2 HRS, and to determine
whether the development of type 1 HRS from pre-existing
type 2 HRS is the same as from pre-existing non-functional
CKD.
6. To determine novel risk factors including cardiac dysfunction
for the development of renal dysfunction and their impact on
prognosis.
Once the various aspects of the different types of HRD are
defined, we will be in a better position to refine the treatment
for renal dysfunction in cirrhosis. The questions that will need
to be answered include:
1. Are the diagnostic criteria for HRS too restrictive? Should the
cut-off value of serum creatinine of 133 mmol/l (1.5 mg/dl)
and 220 mmol/l (2.5 mg/dl) be lowered so that cirrhotic
patients with milder renal failure can be identified and given
treatment earlier?
2. Are treatments for type 1 HRS in patients with underlying
CKD equally efficacious as in those without?
3. In case of non-responsiveness to vasoconstrictors and
albumin, how long does type 1 HRS remain a functional
disease before acute tubular necrosis develops?
Achieving these research goals will go a long way towards
improving the outcome in patients with cirrhosis with renal
dysfunction.
Acknowledgements The authors wish to acknowledge the University of Southern
California for the organisation of this consensus process.
Funding The conferences were supported by unrestricted educational grants from
Ikaria, Gambro Renal Care, Otsuka Pharmaceutical, Nx-Stage Medical, IV League Inc
and Baxter Inc.
Competing interests None.
Contributors FW searched the literature and wrote the paper. MKN organised the
meeting searched the literature. All authors contributed to the content of the paper.
Provenance and peer review Not commissioned; externally peer reviewed.
REFERENCES
1. Garcia-Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis. Hepatology
2008;48:2064e77.
2. Kellum JA, Bellomo R, Ronco C. Acute Dialysis Quality Initiative (ADQI):
methodology. Int J Artif Organs 2008;31:90e3.
3. Flint A. Clinical report on hydroperitoneum based on analysis of 46 cases. Am J Med
Sci 1863;45:306e39.
4. Papper S, Belsky JL, Bleifer KH. Renal failure in Laennec’s cirrhosis of the liver.
I. Description of clinical and laboratory features. Ann Intern Med
1959;51:759e73.
5. Epstein M, Berk DP, Hollenberg NK, et al. Renal failure in the patient with cirrhosis.
The role of active vasoconstriction. Am J Med 1970;49:175e85.
6. Rodes J, Bosch J, Arroyo V. Clinical types and drug therapy of renal impairment in
cirrhosis. Postgrad Med J 1975;51:492e7.
7. Bartoli E, Chiandussi L, eds. Hepato-Renal Syndrome. Padua: Piccin Medical Books,
1979.
8. Anon. Hepatorenal syndrome or hepatic nephropathy? Lancet 1980;315:801e2.
9. Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory
ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology
1996;23:164e76.
10. Salerno F, Gerbes A, Gines P, et al. Diagnosis, prevention and treatment of
hepatorenal syndrome in cirrhosis. Gut 2007;56:1310e18.
11. Laleman W. Role of vasoactive substances and cellular effectors in the
pathophysiology of cirrhotic portal hypertension: the past, the present and the
futureeGeorges Brohée Lecture. Acta Gastroenterol Belg 2009;72:9e16.
12. Rodrı́guez-Vilarrupla A, Fernández M, Bosch J, et al. Current concepts on the
pathophysiology of portal hypertension. Ann Hepatol 2007;6:28e36.
13. Blendis L, Wong F. The hyperdynamic circulation in cirrhosis: an overview.
Pharmacol Ther 2001;89:221e31.
14. Colle I, Geerts AM, Van Steenkiste C, et al. Hemodynamic changes in splanchnic
blood vessels in portal hypertension. Anat Rec (Hoboken) 2008;291:699e713.
15. Arroyo V, Terra C, Gines P. Advances in the pathogenesis and treatment of type-1
and type-2 hepatorenal syndrome. J Hepatol 2007;46:935e46.
16. Cazzaniga M, Salerno F, Visentin S, et al. Increased flow-mediated vasodilation in
cirrhotic patients with ascites: relationship with renal resistive index. Liver Int
2008;28:1396e401.
17. Bernadich C, Bandi JC, Piera C, et al. Circulatory effects of graded diversion of
portal blood flow to the systemic circulation in rats: role of nitric oxide. Hepatology
1997;26:262e7.
18. Bosch J, Pizcueta MP, Fernandez M, et al. Hepatic, splanchnic and systemic
haemodynamic abnormalities in portal hypertension. Baillieres Clin Gastroenterol
1992;6:425e36.
19. Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in
selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology
2004;40:55e64.
20. Wong F, Sniderman K, Liu P, et al. The effects of transjugular intrahepatic
portasystemic shunt on systemic and renal hemodynamics and sodium
homeostasis in cirrhotic patients with refractory ascites. Ann Intern Med
1995;122:816e22.
21. Lang F, Tschernko E, Schulze E, et al. Hepatorenal reflex regulating kidney function.
Hepatology 1991;14:590e4.
22. Solis-Herruzo JA, Duran A, Favela V, et al. Effects of lumbar sympathetic block on
kidney function in cirrhotic patients with hepatorenal syndrome. J Hepatol
1987;5:167e73.
23. Badalamenti S, Graziani G, Salerno F, et al. Hepatorenal syndrome: new
perspectives in pathogenesis and treatment. Arch Intern Med 1993;153:1957e67.
24. Laffi G, La Villa G, Pinzani M, et al. Arachidonic acid derivatives and renal function in
liver cirrhosis. Semin Nephrol 1997;17:530e48.
25. Wong F. Hepatorenal syndrome. In: Lerma EV, Nissenson AR, Berns JS, eds. Current
Diagnosis and Treatment in Nephrology and Hypertension. McGraw Hill: New York
2009:99e108.
26. Stadlbauer V, Wright GA, Banaji M, et al. Relationship between activation of the
sympathetic nervous system and renal blood flow autoregulation in cirrhosis.
Gastroenterology 2008;134:111e19.
27. Wong F. Cirrhotic cardiomyopathy. Hepatol Int 2009;3:294e304.
28. Moller S, Henriksen JH. Cirrhotic cardiomyopathy: a pathophysiological review of
circulatory dysfunction in liver disease. Heart 2002;87:9e15.
29. Ruiz-del-Arbol L, Urman J, Fernandez J, et al. Systemic, renal, and hepatic
hemodynamic derangement in cirrhotic patients with spontaneous bacterial
peritonitis. Hepatology 2003;38:1210e18.
30. Ruiz-del-Arbol L, Monescillo A, Arocena C, et al. Circulatory function and
hepatorenal syndrome in cirrhosis. Hepatology 2005;42:439e47.
31. Jalan R, Forrest EH, Redhead DN, et al. Reduction in renal blood flow following
acute increase in the portal pressure: evidence for the existence of a hepatorenal
reflex in man? Gut 1997;40:664e70.
708 Gut 2011;60:702e709. doi:10.1136/gut.2010.236133
Hepatology
group.bmj.com on November 26, 2014 - Published by http://gut.bmj.com/Downloaded from 
32. Krag A, Bendtsen F, Henriksen JH, et al. Low cardiac output predicts development
of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut
2010;59:105e10.
33. Caregaro L, Menon F, Angeli P, et al. Limitations of serum creatinine level and
creatinine clearance as filtration markers in cirrhosis. Arch Intern Med
1994;154:201e5.
34. Orlando R, Floreani M, Padrini R, et al. Evaluation of measured and calculated
creatinine clearances as glomerular filtration markers in different stages of liver
cirrhosis. Clin Nephrol 1999;51:341e7.
35. Sherman DS, Fish DN, Teitelbaum I. Assessing renal function in cirrhotic patients:
problems and pitfalls. Am J Kidney Dis 2003;41:269e78.
36. Gonwa TA, Jennings L, Mai ML, et al. Estimation of glomerular filtration rates before
and after orthotopic liver transplantation: evaluation of current equations. Liver
Transpl 2004;10:301e9.
37. MacAulay J, Thompson K, Kiberd BA, et al. Serum creatinine in patients with
advanced liver disease is of limited value for identification of moderate renal
dysfunction: are the equations for estimating renal function better? Can J
Gastroenterol 2006;20:521e6.
38. Gaspari F, Perico N, Remuzzi G. Measurement of glomerular filtration rate. Kidney
Int 1997;63(Suppl):S151e4.
39. Davenport A. Difficulties in assessing renal function in patients with cirrhosis:
potential impact on patient treatment. Intensive Care Med. Published Online First 4
March 2011. PMID: 21373822.
40. Gerbes AL, Gulberg V, Bilzer M, et al. Evaluation of serum cystatin C concentration
as a marker of renal function in patients with cirrhosis of the liver. Gut
2002;50:106e10.
41. Gerbes AL, Benesic A, Vogeser M, et al. Serum NGAL: a sensitive novel marker of
renal impairment in liver cirrhosis? Digestion. In press.
42. Francoz C, Glotz D, Moreau R, et al. The evaluation of renal function and disease in
patients with cirrhosis. J Hepatol 2010;52:605e13.
43. Bellomo R, Ronco C, Kellum JA, et al. Acute renal failure e definition, outcome
measures, animal models, fluid therapy and information technology needs: the
Second International Consensus Conference of the Acute Dialysis Quality Initiative
(ADQI) Group. Crit Care 2004;8:R204e12.
44. Hoste EA, Kellum JA, Katz NM, et al. Epidemiology of acute kidney injury. Contrib
Nephrol 2010;165:1e8.
45. Cruz DN, Bagshaw SM, Ronco C, et al. Acute kidney injury: classification and
staging. Contrib Nephrol 2010;164:24e32.
46. Ricci Z, Cruz D, Ronco C. The RIFLE criteria and mortality in acute kidney injury:
a systematic review. Kidney Int 2008;73:538e46.
47. Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: report of an
initiative to improve outcomes in acute kidney injury. Crit Care 2007;11:R31.
48. Lassnigg A, Schmidlin D, Mouhieddine M, et al. Minimal changes of serum
creatinine predict prognosis in patients after cardiothoracic surgery: a prospective
cohort study. J Am Soc Nephrol 2004;15:1597e605.
49. Jenq CC, Tsai MH, Tian YC, et al. RIFLE classification can predict short-term
prognosis in critically ill cirrhotic patients. Intensive Care Med 2007;33:1921e30.
50. Cholongitas E, Calvaruso V, Senzolo M, et al. RIFLE classification as predictive
factor of mortality in patients with cirrhosis admitted to intensive care unit. J
Gastroenterol Hepatol 2009;24:1639e47.
51. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney
disease: evaluation, classification, and stratification. Am J Kidney Dis
2002;39:S1e266.
52. Levey AS, Bosch JP, Lewis JB, et al; Modification of Diet in Renal Disease
Study Group. A more accurate method to estimate glomerular filtration rate
from serum creatinine: a new prediction equation. Ann Intern Med
1999;130:461e70.
53. Michl P, Gulberg V, Bilzer M. Transjugular intrahepatic portosystemic shunt for
cirrhosis and ascites: Effects in patients with organic or functional renal failure. Scand
J Gastroenterol 2000;35:654e8.
54. Rossle M, Gerbes AL. TIPS for the treatment of refractory ascites, hepatorenal
syndrome and hepatic hydrothorax: a critical update. Gut 2010;59:988e1000.
APPENDIX 1
Participants of the joint ADQIeIAC meeting
Jawad Ahmad, Mount Sinai Hospital, USA; Ali Al-Khafaji, University of Pittsburgh
School of Medicine, USA; Paolo Angeli, University of Padova, Italy; Vincente Arroyo,
University of Barcelona, Spain; Rinaldo Bellomo, Melbourne University, Australia; Pat
Brophy, University of Iowa, USA; Jorge Cerda, Albany Medical College, USA; Mink
Chawla, George Washington Medical Center, USA; Andrew Davenport, University
College London Medical School, UK; Connie Davis, University of Washington, USA;
Yuri Genyk, University of Southern California, USA; Alexander Gerbes, Ludwig-Maxi-
milians-Universität München, Germany; Noel Gibney, University of Alberta, Canada;
Rajiv Jalan, University College London Medical School, UK; John A Kellum, University
of Pittsburgh School of Medicine, USA; Mitra K Nadim, University of Southern Cali-
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